GLPGF News and Press, Galapagos Genomics Ord

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual Euro...

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown enc...

BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access ...

2024-05-04 11:51:01 ET Galapagos NV (GLPG) Q1 2024 Results Conference Call May 03, 2024 08:00 AM ET Company Participants Sofie Van Gijsel - Investor Relations Paul Stoffels - Chief Executive Officer Thad Huston - Chief Financial Officer and Chief Operating Office...

Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunology Executed agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier Medicines ...

Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024 were approved. The AGM approved, amongst...

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT) Mechelen, Belgium; 4 April 2024, 22:01 CET – Galapagos NV (Euronext & NASDAQ...

Publication of annual report for financial year 2023 Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board members Extraordinary Shareholders’ Meeting resolutions include approval of renewal of authorize...

Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation. Andrew Dickinson is Gile...

2024-02-23 10:23:03 ET Galapagos NV (GLPG) Q4 2023 Earnings Conference Call February 23, 2024 8:00 AM ET Company Participants Sofie Van Gijsel - Investor Relations Paul Stoffels - Chief Executive Officer Thad Huston - Chief Financial Officer and Chief Operating O...